In a bid to expand its neuroscience portfolio beyond its flagship product Ingrezza® (valbenazine), Neurocrine Biosciences has agreed to develop and commercialise seven of Takeda Pharmaceutical’s pipeline programmes: TAK-831 for schizophrenia, TAK-653 for treatment-resistant depression, TAK-041 for anhedonia, as well as four undisclosed preclinical assets in rare neurological diseases.The deal follows similar deals signed by Neurocrine to bolster its pipeline with Voyager Therapeutics and Xenon Pharmaceuticals.